title: [Effects of roncoleukin on immune parameters and mixed anxiety/depression state induced by chronic social defeat stress in male mice].
abstract: Chronic social defeat stress leads to the development of mixed anxiety-depression state, which accompanied by immune deficiency in male mice. Paper aimed to study effects of ronkoleukin on the parameters of cellular immunity in the thymus and spleen and psychoemotional state in these animals.
  
  
  METHODS
  Mixed anxiety/depression state was produced by chronic social defeat stress during 20 days in male mice. Roncoleukin (5000 ME/kg, i/p) and saline were chronically injected to depressive mice during 2 weeks without agonistic interactions. After this period subpopulations of lymphocytes in the thymus and spleen were studied in male mice. The animals were also studied in behavioral tests estimating the levels of communicativeness, anxiety and depressiveness.
  
  
  RESULTS
  Roncoleukin decreases the number of lymphocytes in the thymus and spleen, and increased the number of lymphocytes in blood and thymus index. Medication increased per cent of CD4+8+ lymphocytes in the thymus and per cent of CD8+ and CD3+25- lymphocytes in the spleen. Roncoleukin induced anxiogenic, stimulative and antidepressive effects.
  
  
  CONCLUSIONS
  Roncoleukin has small efficacy for treatment of immune suppression induced by chronic social defeat stress and has anxiogenic, stimulating and weak antidepressive effects.
authors.forename: A V
authors.initials: AV
authors.lastname: Shurlygina
authors.forename: A G
authors.initials: AG
authors.lastname: Galiamina
authors.forename: E V
authors.initials: EV
authors.lastname: Mel'nikova
authors.forename: N G
authors.initials: NG
authors.lastname: Panteleeva
authors.forename: M V
authors.initials: MV
authors.lastname: Tenditnik
authors.forename: V A
authors.initials: VA
authors.lastname: Trufakin
authors.forename: N N
authors.initials: NN
authors.lastname: Kudriavtseva
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001007:Anxiety / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D001522:Behavior, Animal / Q000187:drug effects; D003863:Depression / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D007111:Immunity, Cellular / Q000187:drug effects; D007113:Immunity, Innate / Q000187:drug effects; D016867:Immunocompromised Host; D007155:Immunologic Factors / Q000494:pharmacology*; D016130:Immunophenotyping; D007274:Injections, Intraperitoneal; D007376:Interleukin-2 / Q000494:pharmacology*; D018655:Lymphocyte Count; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D013154:Spleen / Q000187:drug effects / Q000276:immunology; D013315:Stress, Psychological / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D013950:Thymus Gland / Q000187:drug effects / Q000276:immunology
chemical_list: D000928:Antidepressive Agents; D007155:Immunologic Factors; D007376:Interleukin-2